Keros Therapeutics, Inc.

KROS

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001664710

SEC filings (opens in a new tab)

In the last 90 days, Keros Therapeutics, Inc. insiders filed 2 open-market purchases and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $198.6M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Keros Therapeutics, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024 All holders in Q2 2024

13F holders of KROS: Q2 2024 compared with Q3 2024
Measure	Q2 2024	Of which not filed for Q3 2024	Q3 2024	Change
Holders	152	1	164	+13
Shares	31.5M	2.51M	34.9M	+5.97M (+20.6%)
Value	$1.44B	$114.9M	$2.03B	+$706.6M (+53.4%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (28)

Institutions that held Keros Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to KROS in Q3 2024
Institution	Shares	Value	% of portfolio
BlackRock, Inc.	2,632,608	$152.9M	0.00%
Paradigm Biocapital Advisors LP	525,037	$30.5M	1.07%
Frontier Capital Management Co LLC	287,484	$16.7M	0.16%
Mangrove Partners	286,995	$16.7M	1.61%
Emerald Advisers, LLC	155,545	$9.03M	0.35%
Emerald Mutual Fund Advisers Trust	112,613	$6.54M	0.34%
StemPoint Capital LP	86,930	$5.05M	1.51%
Altium Capital Management LP	69,000	$4.01M	1.19%
Comerica Bank	25,791	$1.50M	0.01%
Northwestern Mutual Wealth Management Co	17,674	$1.03M	0.00%
B. Metzler seel. Sohn & Co. Holding AG	16,103	$935.1K	0.01%
Wellington Management Group LLP	14,949	$868.1K	0.00%
Intech Investment Management LLC	10,392	$603.5K	0.01%
Valence8 US LP	8,025	$466.0K	0.20%
AlphaCentric Advisors LLC	8,000	$464.6K	0.35%
Fox Run Management, L.L.C.	6,144	$356.8K	0.08%
HRT Financial LP	5,807	$337.0K	0.00%
Brevan Howard Capital Management LP	5,718	$332.0K	0.02%
Victory Capital Management Inc	3,716	$215.8K	0.00%
LMR Partners LLP	3,671	$213.2K	0.00%
Pictet Asset Management Holding SA	3,527	$204.8K	0.00%
Acadian Asset Management LLC	2,058	$119.0K	0.00%
Values First Advisors, Inc.	1,528	$88.7K	0.05%
CIBC Private Wealth Group, LLC	250	$14.5K	0.00%
Smartleaf Asset Management LLC	55	$3.10K	0.00%
Sterling Capital Management LLC	30	$1.74K	0.00%
Bessemer Group Inc	25	$1.00K	0.00%
J.Safra Asset Management Corp	6	$339	0.00%

Sold out (15)

Institutions that held Keros Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of KROS in Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
Adage Capital Partners GP, L.L.C.	230,000	$10.5M
Superstring Capital Management LP	74,288	$3.39M
Hudson Bay Capital Management LP	30,038	$1.37M
ExodusPoint Capital Management, LP	19,940	$911.0K
Renaissance Technologies LLC	14,300	$653.5K
SG Americas Securities, LLC	11,633	$532.0K
Dark Forest Capital Management LP	6,355	$290.4K
Principal Financial Group Inc	5,265	$240.6K
Exchange Traded Concepts, LLC	5,167	$236.1K
XTX Topco Ltd	4,996	$228.3K
Aquatic Capital Management LLC	1,200	$54.8K
Pacer Advisors, Inc.	327	$14.9K
HighMark Wealth Management LLC	75	$3.43K
Innealta Capital, LLC	22	$1.00K
National Bank of Canada	10	$437

Not filed for Q3 2024 yet (1)

Institutions that held Keros Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding KROS in Q2 2024 that haven't filed for Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
BlackRock Inc.	2,513,244	$114.9M